IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 22.5

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-01 )

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.57% 19% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.57% 19% F 32% F
Trailing 12 Months  
Capital Gain -7.94% 19% F 21% F
Dividend Return 0.45% 38% F 5% F
Total Return -7.48% 19% F 18% F
Trailing 5 Years  
Capital Gain -26.25% 10% F 17% F
Dividend Return 3.00% 53% F 7% C-
Total Return -23.25% 10% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -7.30% 5% F 8% B-
Dividend Return -6.75% 5% F 7% C-
Total Return 0.55% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 29.27% 14% F 36% F
Risk Adjusted Return -23.07% 5% F 10% F
Market Capitalization 0.12B 60% D- 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.